Research and Markets has announced the addition of the "Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 220.127.116.11 or EC 18.104.22.168) - Pipeline Review, H2 2016" report to their offering.
Macrophage Migration Inhibitory Factor pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2016, outlays comprehensive information on the Macrophage Migration Inhibitory Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Migration Inhibitory Factor targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/n4hnvd/macrophage
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005779/en/Business Wire
Last updated on: 17/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.